Parkman Healthcare Partners’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Parkman Healthcare Partners’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-100,747	Closed	-$10.9M	–	99
2021 Q4	$10.9M	Buy	100,747 +20,980	+26%	+$2.29M	2.4%	14
2021 Q3	$8.74M	Buy	79,767 +7,500	+10%	+$779K	2.21%	16
2021 Q2	$6.77M	Buy	72,267 +3,837	+6%	+$353K	1.48%	24
2021 Q1	$6.3M	Sell	68,430 -107,282	-61%	-$9.05M	1.46%	24
2020 Q4	$12.9M	Sell	175,712 -61,242	-26%	-$4.55M	3.29%	2
2020 Q3	$18.4M	Sell	236,954 -24,952	-10%	-$1.72M	4.87%	1
2020 Q2	$14.6M	Buy	261,906 +15,000	+6%	+$642K	4.1%	3
2020 Q1	$7.31M	Sell	246,906 -18,934	-7%	-$641K	3.39%	7
2019 Q4	$9.62M	Buy	+265,840	New	+$8.15M	2.78%	10

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Parkman Healthcare Partners's HZNP Position: Q1 2022 in Review

Parkman Healthcare Partners sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q1 2022, closing a stake of 100,747 shares — an estimated $10.9M sold.

Parkman Healthcare Partners first reported a position in HZNP in Q4 2019 and held it in 9 quarters. The position peaked at $18.4M in Q3 2020. 620 funds tracked by Wall St. Rank hold HZNP as of Q1 2022.

Parkman Healthcare Partners reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q1 2022 after selling out during the quarter.
Parkman Healthcare Partners sold 100,747 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q1 2022, an estimated $10.9M.
Parkman Healthcare Partners first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2019 and held it in 9 quarters.
Parkman Healthcare Partners's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $18.4M in Q3 2020.
620 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q1 2022.

Based on Parkman Healthcare Partners's 13F filing for Q1 2022, filed 13 May 2022.